Back to top
more

Cara Therapeutics (CARA)

(Delayed Data from NSDQ)

$0.35 USD

0.35
111,559

0.00 (-0.80%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $0.35 0.00 (0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 26th

BJRI, CARA, BOOM, STNG, and UL have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2021.

Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update

Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.

CARA Drug Wins FDA Nod for Pruritus Associated With CKD

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

Cara Therapeutics (CARA) Reports Q2 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -10.91% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 24.19% and -80.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cara (CARA) Surges 14%: Is This an Indication of Further Gains?

Cara (CARA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

Cara Therapeutics' (CARA) Korsuva NDA Gets FDA Priority Review

The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.

Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.

Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?

Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.

Palatin (PTN) to Report Q2 Earnings: What's in the Cards?

Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.

Are Options Traders Betting on a Big Move in Cara Therapeutics (CARA) Stock?

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235

Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.

Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri

Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.

Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA

Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.

XOMA Catches Eye: Stock Jumps 7.9%

XOMA saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA

The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.

Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study

Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.

Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study

Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.

Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion

Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.